GlassScriptPhysician profile
Kenneth J Pechman
NPI 1417956525
$2,562.90
in general payments reported to CMS, 2019-2025
20 companies · $38.66 in 2025
The $38.66 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $110 · 2021: $523 · 2022: $452 · 2023: $385 · 2024: $739 · 2025: $38.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.72 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $332.82 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $322.77 | 2019-2024 | |
| Abbvie INC. | $309.08 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $251.65 | 2019-2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $224.13 | 2021-2022 | |
| Ucb, INC. | $180.20 | 2019-2024 | Bimzelx, Cimzia |
| Genzyme Corporation | $144.16 | 2021-2024 | |
| Pfizer INC. | $120.16 | 2019-2024 | |
| Amgen INC. | $111.53 | 2021-2025 | Otezla |
| Galderma Laboratories, L.P. | $98.72 | 2019-2024 | Aklief |
| Sun Pharmaceutical Industries INC. | $85.50 | 2020-2023 | Ilumya |
| Arcutis Biotherapeutics, INC. | $60.82 | 2024-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.70 | 2019 | |
| Lilly USA, LLC | $57.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.18 | 2022-2024 | Sotyktu |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51.87 | 2019 | |
| Paratek Pharmaceuticals, INC. | $36.68 | 2024 | Nuzyra |
| Dermira, INC. | $24.41 | 2021 | |
| Fresenius Kabi USA, LLC | $21.60 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Pechman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.